Aviragen Therapeutics Inc

Atea Pharmaceuticals Inc. a clinical-stage biopharmaceutical company focused on discovering developing and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527 an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752 a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281 a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection including dengue fever yellow fever and Zika virus as well as Ruzasvir an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated oral pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co Inc. development manufacture and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals Inc. was incorporated in 2012 and is headquartered in Boston Massachusetts.